{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:02:08Z","timestamp":1782903728653,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.eclinm.2023.102231","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T05:56:27Z","timestamp":1695275787000},"page":"102231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial"],"prefix":"10.1016","volume":"64","author":[{"given":"Xiaoqiang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4171-9794","authenticated-orcid":false,"given":"Zhonghan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianhui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luhui","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxiang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6626-1316","authenticated-orcid":false,"given":"Huiling","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoyun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1129-3147","authenticated-orcid":false,"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.eclinm.2023.102231_bib2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102231_bib3","first-page":"195","article-title":"The effects of the COVID-19 pandemic on community respiratory virus activity","volume":"21","author":"Chow","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"14","key":"10.1016\/j.eclinm.2023.102231_bib4","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJMc2202542","article-title":"Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron","volume":"386","author":"Regev-Yochay","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102231_bib5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41591-023-02241-7","article-title":"Determinants of COVID-19 vaccination status and hesitancy among older adults in China","volume":"29","author":"Wang","year":"2023","journal-title":"Nat Med"},{"issue":"10308","key":"10.1016\/j.eclinm.2023.102231_bib6","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(21)02046-8","article-title":"Considerations in boosting COVID-19 vaccine immune responses","volume":"398","author":"Krause","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2023.102231_bib8","article-title":"Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variants","author":"Tan","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.eclinm.2023.102231_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101680","article-title":"Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: a randomised, double-blinded, placebo-controlled, phase 2 trial","volume":"54","author":"Zhang","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"10321","key":"10.1016\/j.eclinm.2023.102231_bib10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0140-6736(21)02753-7","volume":"399","author":"Halperin","year":"2022","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.eclinm.2023.102231_bib11","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa2202261","article-title":"Efficacy and safety of the RBD-dimer-based Covid-19 vaccine ZF2001 in adults","volume":"386","author":"Dai","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102231_bib12","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1021\/acsnano.0c08379","article-title":"Rapid development of SARS-CoV-2 spike protein receptor-binding domain self-assembled nanoparticle vaccine candidates","volume":"15","author":"Kang","year":"2021","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102231_bib13","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S2666-5247(21)00307-4","article-title":"WHO international standard for SARS-CoV-2 antibodies to determine markers of protection","volume":"3","author":"Zhu","year":"2022","journal-title":"Lancet Microbe"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102231_bib14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1473-3099(19)30126-4","article-title":"Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials","volume":"19","author":"Clark","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102231_bib15","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102231_bib16","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1473-3099(23)00199-8","article-title":"Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged \u226518 years: a randomised, double-blind, phase 2b trial","volume":"23","author":"Wu","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"10324","key":"10.1016\/j.eclinm.2023.102231_bib17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"Costa Clemens","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102231_bib18","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.vaccine.2023.01.032","article-title":"Safety and efficacy of COVID-19 prime-boost vaccinations: homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals","volume":"41","author":"Mallah","year":"2023","journal-title":"Vaccine"},{"issue":"683","key":"10.1016\/j.eclinm.2023.102231_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade6023","article-title":"Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose","volume":"15","author":"Filardi","year":"2023","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.eclinm.2023.102231_bib20","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.3390\/vaccines10101655","article-title":"A\u00a0comprehensive review on the current vaccines and their efficacies to combat SARS-CoV-2 variants","volume":"10","author":"Rabaan","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102231_bib21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102231_bib22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41591-023-02212-y","article-title":"Estimating the transmission dynamics of SARS-CoV-2 Omicron BF.7 in Beijing after adjustment of the zero-COVID policy in November-December 2022","volume":"29","author":"Leung","year":"2023","journal-title":"Nat Med"},{"issue":"10377","key":"10.1016\/j.eclinm.2023.102231_bib23","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0140-6736(23)00129-0","article-title":"Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis","volume":"401","author":"Pan","year":"2023","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.eclinm.2023.102231_bib24","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine","volume":"386","author":"Moreira","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102231_bib25","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S1473-3099(22)00271-7","volume":"22","author":"Munro","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"27","key":"10.1016\/j.eclinm.2023.102231_bib26","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10275","key":"10.1016\/j.eclinm.2023.102231_bib27","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102231_bib28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000519853","article-title":"Psychosocial factors predict COVID-19 vaccine side effects","volume":"91","author":"Geers","year":"2022","journal-title":"Psychother Psychosom"},{"issue":"10319","key":"10.1016\/j.eclinm.2023.102231_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(21)02718-5","article-title":"Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial","volume":"399","author":"Stuart","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102231_bib30","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1038\/s41467-022-33169-0","article-title":"Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil","volume":"13","author":"Ranzani","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102231_bib31","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s41467-023-36566-1","article-title":"Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes","volume":"14","author":"Grewal","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2023.102231_bib32","article-title":"Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4\/5 variants at 3 to 4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination","author":"Assawakosri","year":"2022","journal-title":"medRxiv"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702300408X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702300408X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T07:35:54Z","timestamp":1732088154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258953702300408X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":30,"alternative-id":["S258953702300408X"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102231","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102231","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102231"}}